Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Familial Primary Pulmonary Hypertension Clear all

Conditions: Primary Pulmonary Hypertension
Interventions: LIQ861 Inhaled Treprostinil; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 38
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more

Conditions: PAH
Interventions: 75mg CXA-10, 150mg CXA-10, Placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Pulmonary Artery Hypertension
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions: Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4; Other · Drug
Lead sponsor: D. Walter Wray; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2030
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Hypertension
Interventions: Ultrasound Doppler; Radiation
Lead sponsor: Echosense Ltd.; Industry
Eligibility: Not listed
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2021
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Esuberaprost, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 43
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more

Conditions: Pulmonary Artery Hypertension
Interventions: Metformin, Placebo, mHealth Intervention, Usual Care; Drug · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Nashvile, Tennessee

Conditions: Pulmonary Hypertension
Interventions: BQ-123; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions: Bardoxolone methyl, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
Interventions: Sitaxsentan, Bosentan, Ambrisentan; Drug
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Postpartum Haemorrhage (PPH), PPH, Postpartum Hemorrhage (Primary)
Interventions: Alma System; Device
Lead sponsor: ResQ Medical Ltd; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 15 Years to 80 Years
Enrollment: 150 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: BSF 208075; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 687 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Interventions: No Intervention; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis, Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
Interventions: Diltiazem Hydrochloride, Sugar Pill; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions: Iloprost or placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 17
States / cities: Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more

Conditions: Pulmonary Artery Hypertension
Interventions: reserpine, stellate ganglion block, lidocaine; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pulmonary Artery Hypertension, Congenital Heart Disease, Structural Heart Disease
Interventions: MRI Heart guidewire catheterization; Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions: Temporary right ventricular pacing; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: PAH
Interventions: CXA-10; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more

Search by objective public record fields.

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Vascular Subphenotypes of Lung Disease in HIV & COPD

: Vascular Function in Health and Disease

Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

The Role of Endothelin in Pulmonary Hypertension

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Pharmacogenomics in Pulmonary Arterial Hypertension

Pulmonary Hypertension Biorepository and Registry

EVE TRIAL , ALMA SYSTAM

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires

Right Ventricular Pacing in Pulmonary Arterial Hypertension

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension